Transient immunologic effects of betamethasone in human pregnancy after suppression of preterm labor.
Maternal immune suppression is a potentially significant adverse effect when betamethasone is used to hasten lung maturation of the fetus at risk for preterm delivery. However, increased incidence of infection has not been observed consistently after betamethasone treatment of pregnant women. This study was designed to determine if the cellular immune response to steroids may be modified during pregnancy in a way that would diminish the infection risk associated with steroid treatment. The effect of betamethasone on immunocytes among patients with preterm labor or in nonpregnant subjects were determined following administration of 12 mg of betamethasone intramuscularly. We measured serially the circulating leukocytes, lymphocytes, T lymphocytes, and their subsets. Measurements were also made of localized leukocyte mobilization to serum-filled skin chambers covering experimental inflammatory sites. Patients in preterm labor had increased WBC counts prior to treatment with betamethasone but no additional leukocytosis was induced nor was mobilization of leukocytes to the skin chambers decreased. Lymphopenia and depression of T cells was more transient among pregnant patients compared to nonpregnant. Thus, the pregnant patients studied had diminished or more transient potentially adverse immunocyte responses to betamethasone as compared to nonpregnant subjects.
D001623:Betamethasone / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects* / Q000276:immunology; D007964:Leukocytosis / Q000139:chemically induced; D008214:Lymphocytes / Q000187:drug effects; D008231:Lymphopenia / Q000139:chemically induced; D007752:Obstetric Labor, Premature / Q000188:drug therapy*; D011247:Pregnancy; D013997:Time Factors
D007166:Immunosuppressive Agents; D001623:Betamethasone